On 27 April 2010, ENVI (The Committee on the Environment, Public Health and Food Safety) of the European Parliament voted to adopt reports on both falsified medicines and pharmacovigilance. The measures included in these reports are intended to increase patients’ safety. This can only be good news for the generics sector, as this should result in increased consumer confidence and as a result encourage acceptance and increase sales of generics.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
- Impact of e-bidding procurement on generic omeprazole injection prices in Thailand
-
Biosimilars
News
- Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
- EMA recommends approval of ustekinumab biosimilar Pyzchiva
- FDA approves interchangeable adalimumab biosimilar Simlandi
- EC approval of ranibizumab biosimilar Rimmyrah
Research
- Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
- ANVISA's role in biosimilar medicine regulation and innovation promotion
- Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
- Biological therapies for psoriasis: evaluating durability and persistent benefits
- MORE EDITORIAL SECTIONS
- Search
Comments (0)
Post your comment